PreventionFMSrugbyAMANCT06715618
The Use of the Functional Movement Screen™ in Preventing Injuries in Amateur Rugby Players
An observational study of Prevention and Risk, run by Hopital La Musse at 1 site in France.
Trial summary
Rugby is a team contact sport that demands unparalleled physical engagement. This practice, which combines random running patterns with changes in speed and direction, also involves frequent contact situations with other players. These phases of the game account for 48% to 80% of total injuries. Read more about this study
- Who is it for?
- Ages 18 years and older, men onlyHealthy volunteers can take part
- Conditions the study is for
- Prevention, Risk, Injuries
- What is being tested?
- FMS test
- How many people
- 20 participants
- Where
- 1 siteFrance
- Study dates
- 3 Oct 2024to 7 May 2025
- Phase
- Observational
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Men only
- Healthy volunteers accepted
- Adult, Older adult
Study population: The chosen study population consists of amateur rugby players from Normandy. Forty rugby players will be included in this study.
Who may be able to join
- Players licensed with the French Rugby Federation (FFR): Their affiliation with the FFR requires a medical certificate confirming no contraindication to competitive sports practice.
- Players aged at least 18 years old, legally adults.
- Healthy players who have not sustained any musculoskeletal injuries or undergone surgical interventions in the past 6 months.
- Players competing in "Fédérale 3."
- Players from clubs based in Normandy.
Who cannot join
- Minor players
- Female players
- Players injured during the first interview or the first FMS™
- Players who are or have been professional athletes
- Players with a history of frequent serious injuries that could pose a risk to their continued participation
Trial locations and contacts
1 site in 1 country.
About this study
Official title: The Use of the Functional Movement Screen™ in Preventing Injuries in Amateur Rugby Players: A Longitudinal Prospective Study
Rugby is a team contact sport that demands unparalleled physical engagement. This practice, which combines random running patterns with changes in speed and direction, also involves frequent contact situations with other players. These phases of the game account for 48% to 80% of total injuries. Injury prevention is an integral part of the physical therapist's expertise and plays a crucial role in reducing the occurrence of musculoskeletal injuries and mitigating their devastating consequences.
The implementation of a risk prevention tool is particularly relevant for a population prone to injuries. However, the practicality of such a tool must be considered, as adherence to an injury prevention program depends on the "perceived usefulness, intensity, and time investment of the program".
Read more
One tool appears to meet these criteria: the Functional Movement Screen™ (FMS™). This tool is designed to "evaluate an individual's functional movement patterns" and, according to its authors, can serve as "a crucial tool" for returning to sports after an injury or a period of inactivity. Given the high incidence of injuries in rugby players, calculating the injury incidence in this population and correlating it with FMS™ scores could provide valuable insights.
For this prospective study, forty amateur rugby players from various clubs in Normandy competing at the Federal 3 level will be recruited using a recruitment letter and a call for volunteers.
Each participant will perform two FMS™ (7 movements), at the beginning of the competitive season and at the end of the competitive season. The test will last 30 minutes per player. The initial interview will last 20 minutes. There will also be a follow-up of the players throughout the season to collect all injuries sustained by participants in the intervention.
The main expected outcome is a significant correlation (p < 0.05) between the FMS™ score and injury incidence. This correlation may then indicate a good predictive capacity of the FMS™, allowing it to be considered a predictive tool for injury risk.
To evaluate the correlation between two variables (injury incidence sustained by the player and the FMS™ score), the Spearman correlation coefficient will be used. This coefficient, if its value approaches -1 or 1, will indicate a good correlation between the player's injury incidence and their FMS™ score. Conversely, if the coefficient approaches 0, the correlation will be considered poor.
In a second phase, it is expected that a competitive season will directly affect the FMS™ score, highlighting the difficulty for an amateur player to maintain their physical capacities throughout an entire season.
- Conditions
- Prevention, Risk, Injuries, Rugby, Rugby Player
- Being tested
- FMS test
- Keywords
- Amateur Rugby, Prevention, Risk, Injuries, Players
- Medical subject headings
- Wounds and Injuries
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
FMS testOther
Each participant will perform two FMS™, one at the beginning of the competitive season. The test will take 30 minutes per player. The initial interview will last 20 minutes. Players will also be monitored throughout the season to collect all injuries sustained by the participants in the study.
| Study group | Role | What they receive |
|---|---|---|
| FMS group | Each participant will perform two FMS™, one at the beginning of the competitive season. The test will take 30 minutes per player. The initial interview will last 20 minutes. Players will also be monitored throughout the season to collect all injuries sustained by the participants in the study. Receives: Other: FMS test |
What is being measured
The primary outcome is the main question the study is designed to answer.
The FMS™ Score
The Functional Movement Screen™ (FMS™) is a tool designed to "evaluate an individual's functional movement patterns" and, according to its authors, can represent "a crucial tool" for returning to sport after an injury or a break from sports. It consists of an assessment of seven so-called fundamental movements, which require good neuromuscular and motor control, as well as balance and stability. These movements aim to place the evaluated subject in extreme positions to highlight significant imbalances throughout the body. This test consists of a score from 0 to 3 for each of the 7 movements, and a final score out of 21 points. The FMS reveals functional deficits by highlighting compensatory movements. The higher the score, the fewer compensatory movements.
Measured: At the beginning of the season (baseline) for each player
Secondary outcomes (1)
Injuries
The secondary endpoint is the number of injuries. An injury is defined as "any physical complaint caused by an energy transfer exceeding the body's ability to maintain its structural and/or functional integrity, sustained by a player, regardless of the need for medical treatment or the time lost due to the injury". Here, only injuries involving time lost, the "time-loss injury," are considered. Therefore, in this study, a player is considered injured if they are unable to participate in the following training session or match due to the injury. Any other inability, such as personal or professional reasons, will not be considered. This method of data collection is widely used in sports medicine due to its simplicity, even when athletes themselves report the injury.
Measured: Through the season, up to 7 months per player
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Dec 2024
- Study start3 Oct 2024
- Primary completion28 Feb 2025
- Study completion7 May 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for PreventionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 20 participants (actual)
Sponsor and investigators
- Lead sponsor
- Hopital La Musse
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06715618
- Sponsor's protocol ID
- 2024-A01804-43
- Acronym
- FMSrugbyAMA
- Status last verified
- Apr 2026
- First submitted
- 28 Nov 2024
- Last updated
- 4 May 2026
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 4 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Use of the Functional Movement Screen™ in Preventing Injuries in Amateur Rugby Players: A Longitudinal Prospective Study
- ClinicalTrials.gov ID
- NCT06715618
- Acronym / sponsor ID
- FMSrugbyAMA / 2024-A01804-43
- Conditions
- Prevention, Risk, Injuries, Rugby, Rugby Player
- Keywords
- Amateur Rugby, Prevention, Risk, Injuries, Players
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 20 participants (actual)
- Lead sponsor
- Hopital La MusseUniversity, hospital or other
- Study start
- 3 Oct 2024 (actual)
- Primary completion
- 28 Feb 2025 (actual)
- Study completion
- 7 May 2025 (actual)
- First posted
- 4 Dec 2024 (actual)
- Results
- Posted 4 May 2026
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Rugby is a team contact sport that demands unparalleled physical engagement. This practice, which combines random running patterns with changes in speed and direction, also involves frequent contact situations with other players. These phases of the game account for 48% to 80% of total injuries. Injury prevention is an integral part of the physical therapist's expertise and plays a crucial role in reducing the occurrence of musculoskeletal injuries and mitigating their devastating consequences.
The implementation of a risk prevention tool is particularly relevant for a population prone to injuries. However, the practicality of such a tool must be considered, as adherence to an injury prevention program depends on the "perceived usefulness, intensity, and time investment of the program".
One tool appears to meet these criteria: the Functional Movement Screen™ (FMS™). This tool is designed to "evaluate an individual's functional movement patterns" and, according to its authors, can serve as "a crucial tool" for returning to sports after an injury or a period of inactivity. Given the high incidence of injuries in rugby players, calculating the injury incidence in this population and correlating it with FMS™ scores could provide valuable insights.
For this prospective study, forty amateur rugby players from various clubs in Normandy competing at the Federal 3 level will be recruited using a recruitment letter and a call for volunteers.
Each participant will perform two FMS™ (7 movements), at the beginning of the competitive season and at the end of the competitive season. The test will last 30 minutes per player. The initial interview will last 20 minutes. There will also be a follow-up of the players throughout the season to collect all injuries sustained by participants in the intervention.
The main expected outcome is a significant correlation (p < 0.05) between the FMS™ score and injury incidence. This correlation may then indicate a good predictive capacity of the FMS™, allowing it to be considered a predictive tool for injury risk.
To evaluate the correlation between two variables (injury incidence sustained by the player and the FMS™ score), the Spearman correlation coefficient will be used. This coefficient, if its value approaches -1 or 1, will indicate a good correlation between the player's injury incidence and their FMS™ score. Conversely, if the coefficient approaches 0, the correlation will be considered poor.
In a second phase, it is expected that a competitive season will directly affect the FMS™ score, highlighting the difficulty for an amateur player to maintain their physical capacities throughout an entire season.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| FMS group | – | Other: FMS testEach participant will perform two FMS™, one at the beginning of the competitive season. The test will take 30 minutes per player. The initial interview will last 20 minutes. Players will also be monitored throughout the season to collect all injuries sustained by the participants in the study. |
Who may qualify
- Ages
- 18 years and older
- Sex
- Male only
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- The chosen study population consists of amateur rugby players from Normandy. Forty rugby players will be included in this study.
Key inclusion criteria (5 listed)
- Players licensed with the French Rugby Federation (FFR): Their affiliation with the FFR requires a medical certificate confirming no contraindication to competitive sports practice.
- Players aged at least 18 years old, legally adults.
- Healthy players who have not sustained any musculoskeletal injuries or undergone surgical interventions in the past 6 months.
- Players competing in "Fédérale 3."
- Players from clubs based in Normandy.
Key exclusion criteria (5 listed)
- Minor players
- Female players
- Players injured during the first interview or the first FMS™
- Players who are or have been professional athletes
- Players with a history of frequent serious injuries that could pose a risk to their continued participation
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| FMS testEach participant will perform two FMS™, one at the beginning of the competitive season. The test will take 30 minutes per player. The initial interview will last 20 minutes. Players will also be monitored throughout the season to collect all injuries sustained by the participants in the study. | Other | FMS group |
Primary outcome
The FMS™ Score
Time frame: At the beginning of the season (baseline) for each player
The Functional Movement Screen™ (FMS™) is a tool designed to "evaluate an individual's functional movement patterns" and, according to its authors, can represent "a crucial tool" for returning to sport after an injury or a break from sports. It consists of an assessment of seven so-called fundamental movements, which require good neuromuscular and motor control, as well as balance and stability. These movements aim to place the evaluated subject in extreme positions to highlight significant imbalances throughout the body. This test consists of a score from 0 to 3 for each of the 7 movements, and a final score out of 21 points. The FMS reveals functional deficits by highlighting compensatory movements. The higher the score, the fewer compensatory movements.
1 secondary outcome
Injuries
Time frame: Through the season, up to 7 months per player
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 May 2026.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Individual participant dataSharing planned: Undecided
Related trials for Prevention
Not yet recruiting
Preventive and Personalized Digital Emotion Regulation Skills Intervention to Reduce Depression and Anxiety in Youths With Adverse Childhood Experiences
Adverse Childhood Experience, Depression / Major Depressive Disorder
Active, not recruitingPhase 3
Study to Evaluate the Efficacy and Safety of Ilaprazole 10 mg in Prevention NSAIDs Associated Peptic Ulcer
Peptic Ulcer
Not yet recruiting
HealthMpowerment Korea: Pilot Testing the Cultural Adaptation of a Digital HIV Intervention for Men Who Have Sex With Men in South Korea
HIV Infections, HIV Prevention and Care
Active, not recruitingPhase 2
De-escalated Cyclophosphamide (PTCy) and Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis
Graft-versus-host Disease
Not yet recruitingObservational study
Pilot Study on the Effectiveness and Safety of OPTILENE® SILVER MESH ELASTIC in Prevention of Surgical Site Infection (SSI) and Incisional Hernia (IH)
Abdominal Aortic Aneurysm, Morbid Obesity
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Prevention and Risk, run by Hopital La Musse at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 4 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Yes. Results are posted in the registry (first posted 4 May 2026). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The FMS™ Score (time frame: At the beginning of the season (baseline) for each player). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 May 2026.